Journal of the Neurological Sciences
Volume 290, Issue 1 , Pages 123-130 , 15 March 2010

Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model

  • Rongqin Huang

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China
    • ,
  • Weilun Ke

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China
    • ,
  • Yang Liu

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China
    • ,
  • Dongdong Wu

      Affiliations

    • Department of Neuropharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
    • ,
  • Linyin Feng

      Affiliations

    • Department of Neuropharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
    • ,
  • Chen Jiang

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China
    • Corresponding Author InformationCorresponding author. Address: Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai, 201203, China. Tel./fax: +86 21 51980079.
    • ,
  • Yuanying Pei

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China

Received 5 August 2009 ,Revised 26 September 2009 ,Accepted 28 September 2009.

References 

  1. Chtarto A, Yang X, Bockstael O, Melas C, Blum D, Lehtonen E, et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol. 2007;204(1):387–399
  2. Schlachetzki F, Zhang Y, Boado R, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology. 2004;62(8):1275–1281
  3. Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 2003;373:507–528
  4. Huang RQ, Ke WL, Liu Y, Jiang C, Pei YY. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29(2):238–246
  5. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson′s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002;175(2):303–317
  6. Liu WG, Lu GQ, Li B, Chen SD. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson′s disease. Parkinsonism Relat Disord. 2007;13(2):77–88
  7. Huang J, Liu H, Gu W, Yan Z, Xu Z, Yang Y, et al. A delivery strategy for rotenone microspheres in an animal model of Parkinson′s disease. Biomaterials. 2006;27(6):937–946
  8. Samantaray S, Knaryan VH, Guyton MK, Matzelle DD, Ray SK, Banik NL. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience. 2007;146(2):741–755
  9. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136(1):317–324
  10. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson′s disease. Neurosci Lett. 2003;341(2):87–90
  11. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson′s disease. Nat Neurosci. 2000;3(12):1301–1306
  12. Sindhu KM, Saravanan KS, Mohanakumar KP. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res. 2005;1051(1–2):25–34
  13. Hirsch EC, Höglinger G, Rousselet E, Breidert T, Parain K, Feger J, et al. Animal models of Parkinson′s disease in rodents induced by toxins: an update. J Neural Transm Suppl. 2003;65:89–100
  14. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson′s disease. Expert Rev Neurother. 2008;8(7):1125–1139
  15. Mochizuki H, Yasuda T, Mouradian MM. Advances in gene therapy for movement disorders. Neurotherapeutics. 2008;5(2):260–269
  16. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson′s disease. Science. 2000;290(5492):767–773
  17. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 2007;21(4):1117–1125
  18. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology. 2003;44(5):642–652
  19. Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res. 2007;42(3):247–253
  20. Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson′s disease. PLoS ONE. 2008;3(1):e1433
  21. da Cruz MT, Cardoso AL, de Almeida LP, Simões S, de Lima MC. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther. 2005;12(16):1242–1252
  22. Xia CF, Boado RJ, Zhang Y, Chu C, Pardridge WM. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson′s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med. 2008;10(3):306–315
  23. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A. 1995;92(21):9603–9607
  24. Huang RQ, Han L, Li JH, Ren FL, Ke WL, Jiang C, et al. Neuroprotection in a 6-OHDA-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med. 2009;11(9):754–763
  25. Chen X, Liu W, Guoyuan Y, Liu Z, Smith S, Calne DB, et al. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson′s disease. Parkinsonism Relat Disord. 2003;10(1):1–7
  26. Zhang Y, Pardridge WM. Near complete rescue of experimental Parkinson′s disease with intravenous, non-viral GDNF gene therapy. Pharm Res. 2009;26(5):1059–1063
  27. Pedersen LM, Jacobsen LM, Mollerup S, G jerstad J. Spinal cord long-termpotentiation (LTP) is associated with increased dorsal horn gene expression of IL-1beta, GDNF and iNOS. Eur J Pain in press, doi:10.1016/j.ejpain.2009.05.016.

PII: S0022-510X(09)00892-2

doi: 10.1016/j.jns.2009.09.032

Journal of the Neurological Sciences
Volume 290, Issue 1 , Pages 123-130 , 15 March 2010

Article Tools

* Image Usage & Resolution